KR910002774A - 2-아미노펜탄 산 화합물 및 면역 억제제로 그들을 사용하는 방법 - Google Patents

2-아미노펜탄 산 화합물 및 면역 억제제로 그들을 사용하는 방법 Download PDF

Info

Publication number
KR910002774A
KR910002774A KR1019900010213A KR900010213A KR910002774A KR 910002774 A KR910002774 A KR 910002774A KR 1019900010213 A KR1019900010213 A KR 1019900010213A KR 900010213 A KR900010213 A KR 900010213A KR 910002774 A KR910002774 A KR 910002774A
Authority
KR
South Korea
Prior art keywords
alkyl
aminopentanoic acid
immunosuppressants
acid compounds
compounds
Prior art date
Application number
KR1019900010213A
Other languages
English (en)
Other versions
KR950013101B1 (ko
Inventor
데쯔로 후지다
다케시 이구모토
시게오 사사키
겐지 시바
유키오 호시노
Original Assignee
고오야 다다시
요시토미 세이야쿠 가부시기가이샤
다케이 노부오
다이토 가부시기가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 고오야 다다시, 요시토미 세이야쿠 가부시기가이샤, 다케이 노부오, 다이토 가부시기가이샤 filed Critical 고오야 다다시
Publication of KR910002774A publication Critical patent/KR910002774A/ko
Application granted granted Critical
Publication of KR950013101B1 publication Critical patent/KR950013101B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32—Oxygen atoms
    • C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/22—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated the carbon skeleton being further substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/30—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and unsaturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/32—Oximes
    • C07C251/34—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C251/36—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with the carbon atoms of the oxyimino groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C251/40—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with the carbon atoms of the oxyimino groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of an unsaturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D339/00—Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms
    • C07D339/02—Five-membered rings
    • C07D339/06—Five-membered rings having the hetero atoms in positions 1 and 3, e.g. cyclic dithiocarbonates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

내용 없음

Description

2-아미노펜탄 산 화합물 및 면역 억제제로 그들을 사용하는 방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (3)

  1. 하기 일반식(I)로 표시되는 2-아미노펜탄 산, 그들의 염, 그들의 r-락톤 화합물 및 그것의 보호성기에 의해 보호된 화합물.
    (상기식에서, R은 알킬, 히드록시 알킬, -CH=CH(CH2)nCH=CH-CH(OH)-(CH2)mCH3로 표시되는 기, -CH=CH(CH2)p-C-(=X)-(CH2)qCH3로 포시되는 기 또는 -CH=CH-Y로 표시되는 기이고, 여기에서 n 및 m은 각각 1 내지 10의 정수를 의미하며, >C=X 는 B는 수소 또는 알킬인 >C=N-OB, 또는 >CHNH2또는 A가 알킬렌인 >를 의미하며, p 및 q는 각각 1 내지 10의 정수이고, Y는 알킬이다).
  2. 제1항에 있어서, 하기 화합물(a) 내지 (f)중에서 선택된 화합물, 또는 그들의 이성체 또는 그들의 약학적 허용염인 화합물.
  3. 제1항 또는 제2항의 화합물을 포함하는 면역 억제제.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019900010213A 1989-07-07 1990-07-06 2-아미노펜탄산 화합물 및 면역 억제제로 그들을 사용하는 방법 KR950013101B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP176914 1989-07-07
JP17691489 1989-07-07
JP1-176914 1989-07-07

Publications (2)

Publication Number Publication Date
KR910002774A true KR910002774A (ko) 1991-02-26
KR950013101B1 KR950013101B1 (ko) 1995-10-24

Family

ID=16021968

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019900010213A KR950013101B1 (ko) 1989-07-07 1990-07-06 2-아미노펜탄산 화합물 및 면역 억제제로 그들을 사용하는 방법

Country Status (4)

Country Link
US (1) US5068247A (ko)
EP (1) EP0410176A1 (ko)
KR (1) KR950013101B1 (ko)
CA (1) CA2020655A1 (ko)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5233062A (en) * 1992-03-16 1993-08-03 Merck & Co., Inc. Antibiotic eicosenoic acids
ES2126658T3 (es) * 1992-10-21 1999-04-01 Yoshitomi Pharmaceutical Compuesto de 2-amino-1,3-propanodiol e inmunosupresor.
US5948820A (en) * 1994-08-22 1999-09-07 Yoshitomi Pharmaceutical Industries, Ltd. Benzene compound and pharmaceutical use thereof
GB9518417D0 (en) * 1995-09-08 1995-11-08 Fujisawa Pharmaceutical Co Novel compound
US20030220234A1 (en) 1998-11-02 2003-11-27 Selvaraj Naicker Deuterated cyclosporine analogs and their use as immunodulating agents
EP1554572B1 (en) 2001-07-25 2009-10-14 Raptor Pharmaceutical Inc. Compositions and methods for modulating blood-brain barrier transport
WO2003033526A2 (en) 2001-10-19 2003-04-24 Isotechnika Inc. Synthesis of cyclosporin analogs
BR0306811A (pt) * 2002-01-11 2004-10-26 Sankyo Co Composto, éster farmacologicamente aceitável do mesmo, composição farmacêutica e métodos para prevenção ou tratamento de doenças autoimunes, da artrite reumatóide e da rejeição causada pelo transplante de vários órgãos em um mamìfero
AU2005215320B2 (en) 2004-02-24 2008-04-17 Sankyo Company, Limited Amino alcohol compound
BRPI0515992A (pt) * 2004-10-12 2008-08-19 Forbes Medi Tech Res Inc compostos e métodos para o tratamento de resistência à insulina e cardiomiopatia
US20070135450A1 (en) * 2004-10-12 2007-06-14 Forbes Medi-Tech (Research), Inc. Compounds and Methods of Treating Insulin Resistance and Cardiomyopathy
EP3827747A1 (en) 2005-04-28 2021-06-02 Otsuka Pharmaceutical Co., Ltd. Pharma-informatics system
EP2063905B1 (en) 2006-09-18 2014-07-30 Raptor Pharmaceutical Inc Treatment of liver disorders by administration of receptor-associated protein (rap)-conjugates
ES2942923T3 (es) 2009-05-06 2023-06-07 Laboratory Skin Care Inc Composiciones de administración dérmica que comprenden complejos de agente activo-partículas de fosfato de calcio y métodos de uso de las mismas
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3928572A (en) * 1971-02-11 1975-12-23 Ayerst Mckenna & Harrison Myriocin and process of preparation
US3758529A (en) * 1971-03-23 1973-09-11 Sir Soc Italiana Resine Spa Antibiotic thermozymocidin and a process for its preparation
WO1990002727A1 (en) * 1988-09-14 1990-03-22 Yoshitomi Pharmaceutical Industries, Ltd. Immunosuppressant

Also Published As

Publication number Publication date
KR950013101B1 (ko) 1995-10-24
US5068247A (en) 1991-11-26
CA2020655A1 (en) 1991-01-08
EP0410176A1 (en) 1991-01-30

Similar Documents

Publication Publication Date Title
KR910002774A (ko) 2-아미노펜탄 산 화합물 및 면역 억제제로 그들을 사용하는 방법
FI940788A0 (fi) Alkoholi- tai aldehydijohdannaiset ja niiden käyttö
SE8004783L (sv) Delta?722-1,2,4triazolin-5-on-derivat
KR950017957A (ko) 3, 4, 4-삼치환-피페리디닐-n-알킬카르복실레이트의 제법 및 중간체
ES2126068T3 (es) Derivados de estilbeno citotoxicos y composicion farmaceutica que los contiene.
DK0659174T3 (da) Derivater af valproinsyre og 2-valproensyreamider samt deres anvendelse som antikonvulsive midler
CA2153979A1 (en) Compounds having both potent calcium antagonist and antioxidant activity and use thereof as cytoprotective agents
KR960013348A (ko) 치과용 살균성 접착제 조성물
ES8400890A1 (es) Procedimiento para la obtencion de emulsiones de aceite-en-agua.
PT1063228E (pt) Derivados de cicloalcenos processo para a sua preparacao e utilizacao
KR920014772A (ko) 방사선 방호제로 유용한 폴리아민 티올
KR960007592A (ko) 신규한 피롤로카바졸
SE8700113L (sv) Pesticid o/w-emulsion
KR910019977A (ko) 카르바졸 화합물
ATE550331T1 (de) Glycosidasehemmer und verfahren zu dessen herstellung
SE8502073D0 (sv) Delta?722-1,2,4-triazolin-5-on-derivat och herbicida kompositioner, som innehaller desamma
KR927003488A (ko) 술폰화제 및 술폰화법
KR890001965A (ko) 스퍼구알린 관련 유도체
KR910004557A (ko) 2,4,6-치환 페놀 유도체
AR245463A1 (es) Polimeros de epihalohidrina/poliamina que contienen bajos niveles de dihalopropanoles, procedimiento para prepararlos, y aprestos para papel preparados con los mismos
KR900016178A (ko) 2-치환 n,n'-디트리메톡시벤조일 피페라진, 그의 제조 방법 및 그를 함유하는 치료 조성물
CA2180621A1 (fr) Nouveaux derives d'acide aminophenylphosphonique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
MX9206930A (es) Nuevos compuestos
KR890008148A (ko) 새로운 세파로스포린 화합물 및 항균제
KR920702685A (ko) 4,6-o- 히드록시포스포릴글루코사민 유도체

Legal Events

Date Code Title Description
A201 Request for examination
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
LAPS Lapse due to unpaid annual fee